Datopotamab Deruxtecan Shows Promising Activity in EGFR-Mutated NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate, showed promising results in a pooled analysis of two clinical trials...
Mirailab Launches NMN Supplements and Cosmetics in UAE
MIRAILAB BIOSCIENCE Inc. has launched its β-Nicotinamide Mononucleotide (β-NMN) supplement brand, “MIRAI LAB,” in the UAE. NMN, found naturally...
Veracyte Decipher Prostate Test Recommended in NCCN Guidelines
Veracyte’s Decipher Prostate Genomic Classifier is the only gene expression test included in the 2025 National Comprehensive Cancer Network...
Envision Trial Shows UGN-102’s Potential for LG-IR-NMIBC Treatment
UroGen Pharma announced positive Phase 3 ENVISION trial results for UGN-102, a mitomycin-based intravesical solution for recurrent low-grade intermediate-risk...
Maat Pharma Announces First US Patient Treated Under Expanded Access for Graft-Versus-Host Disease
MaaT Pharma has administered its investigational microbiome therapeutic, MaaT013, to the first patient in the United States under the...
Iliad Biotech’s Intranasal Pertussis Vaccine Gets Innovation Passport
ILiAD Biotechnologies’ intranasal pertussis vaccine, BPZE1, has received Innovation Passport designation from the UK Medicines & Healthcare Products Regulatory...
MEK Inhibitors Market to Grow by Over $500 Million by 2030
The global market for MEK Inhibitors is predicted to experience substantial growth, increasing from US$995.1 million in 2023 to...
Omniscience and Inmune Bio Partner to Accelerate Alzheimer’s Drug Trial
OmniScience and INmune Bio have partnered to utilize OmniScience’s AI-powered platform, Vivo, in INmune Bio’s Phase 2 Alzheimer’s diseaseAlzheimer’s...
Next-Gen Cancer Diagnostics: ctDNA, CTC, miRNA Testing Drives Growth
The global Next Generation Cancer Diagnostics (NGCD) market is poised for significant expansion, projected to surge from US$16.6 billion...
Ajax Presents Phase 1 Trial Results for Myelofibrosis Treatment
Ajax Therapeutics, a biopharmaceutical company focused on developing advanced JAK inhibitors for myeloproliferative neoplasms (MPNs), will present data from...